Tel Aviv - Delayed Quote ILA

Enlivex Therapeutics Ltd. (ENLV.TA)

Compare
428.30 -27.80 (-6.10%)
At close: December 15 at 3:49:35 PM GMT+2

Key Executives

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in ILA.
NameTitlePayExercisedYear Born
Mr. Shai Novik M.B.A. Executive Chairman 528k -- 1966
Dr. Oren Hershkovitz Ph.D. Chief Executive Officer 273.6k -- 1977
Ms. Shachar Shlosberger CPA Chief Financial Officer 126k -- 1977
Mr. Veronique Amor-Baroukh Senior Director of Operations -- -- --
Ms. Sigal Arad Director of HR -- -- --

Enlivex Therapeutics Ltd.

14 Einstein Street
Ness Ziona, 7403618
Israel
972 2 670 8072 https://www.enlivex.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Corporate Governance

Enlivex Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers